PharmiWeb.com - Global Pharma News & Resources

Biotech - Press Releases

Date Title Company
28-May-2020 Gavi: Partnering to protect future generations from infectious diseases ABPI
28-May-2020 Roche’s Tecentriq gains first-line approval in NSCLC but Keytruda reigns supreme, says GlobalData Roche
28-May-2020 Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints Regeneron
28-May-2020 Immunocore announces dosing of first patient with fourth ImmTAC® Immunocore
28-May-2020 Vectura provides AGM trading update and reiterates 2020 guidance Vectura
28-May-2020 Sareum to Present at BIO Digital 2020 Sareum
28-May-2020 Oxitec’s New Friendly Aedes aegypti Mosquito Technology Receives Full Biosafety Approval in Brazil Oxitec
28-May-2020 Laboratory relocation specialist backs NHS tribute Aport
28-May-2020 Pivotal Preclinical Oncology Platform Expands to Include New Patient-Derived Organoid Models Hubrecht Organoid Technology
28-May-2020 New gut health and immunity white paper launched Clasado Biosciences
28-May-2020 Pneumagen Announces £4m Fundraising and Commits to Clinical Trial Development for COVID-19 Pneumagen
28-May-2020 Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers Cytovation AS
28-May-2020 Sanofi announces pricing of Regeneron stock offering Sanofi
28-May-2020 NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference NuCana plc
28-May-2020 Oxitec’s New Friendly Aedes aegypti Mosquito Technology Receives Full Biosafety Approval in Brazil Oxitec Ltd
28-May-2020 Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation Cidara Therapeutics, Inc
28-May-2020 Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial Synairgen plc
28-May-2020 Faron announces R&D Day to be held in June Faron Pharmaceuticals
28-May-2020 IRBM’s Advent announces manufacture of 13,000 doses of Covid-19 vaccine, for use in Phase 2/3 clinical trials by the University of Oxford IRBM Group
28-May-2020 Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Even Greater Stabilization in Patients Starting Earlier Treatment Akcea Therapeutics, Inc